FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesCurrent Challenges in Cell and Gene Therapy
Topic: Regulatory
Webinar
Free
Direct-to-Patient Survey Results Summary
Topics: Health Care, Innovation, Supply Chain
Report
Free
Requirements of a QP
Topic: Pharma Industry
Video
Members
